2022-502092-33-00
CTIS ↗
ETOP 23-22 RAISE
Extensive-disease small cell lung cancer and high SLFN11-expression
pharma · Breast Cancer · NSCLC, synchronous oligo-metastatic
Impact Therapeutics
Partner Therapeutics Limited
Impact Therapeutics trial registry — 12 ClinicalTrials.gov studies with program phase, status, and indication context.
1004, 10th Floor, Lodha Supremus Saki Vihar Road, Powai, Mumbai-400072, Maharashtra 400072, IN, Lexington HQ
2010 Founded
8 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 1004, 10th Floor, Lodha Supremus Saki Vihar Road, Powai, Mumbai-400072, Maharashtra 400072, IN, Lexington
- Founded
- 2010
- Employees
- 8
- Programs
- 12
- Drugs
- 26
- Patents
- 0
Impact Therapeutics clinical trials
Registry index of 12 ClinicalTrials.gov studies linked to Impact Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Impact Therapeutics trial registry — 12 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Impact Therapeutics.
-
JNJ-73841937 for Patients with EGFR-mutant (L858… — Phase 2
Clinical update -
IBCSG 59-19 — Phase 3
Clinical update -
ETOP 23-22 RAISE — Phase 2
Clinical update -
67-22 PREcoopERA — Phase 2
Clinical update -
ETOP25-23 ADOPT-lung — Phase 3
Clinical update -
ETOP 14-18 CHESS — Phase 2
Clinical update -
LIBTAYO 350 mg concentrate for solution for infusion. — Phase 3
Clinical update -
cyclophosphamide — Phase 3
Clinical update
Trial registry
-
-
CTIS ↗ -
CTIS ↗ - 2023-510463-35-00CTIS ↗
Adagrasib
Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status (ECOG PS=2) Cohort 1 or elderly (≥70 years) (ECOG PS=0-1) Cohort 2
- 2024-510776-20-00CTIS ↗
IBCSG 59-19
Female or male patients with histologically confirmed HR-positive, HER2-negative resected isolated locoregional recurrence (ILRR) of breast cancer.
-
CTIS ↗ - 2024-512288-29-00CTIS ↗
JNJ-73841937 for Patients with EGFR-mutant (L858…
Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous NSCLC, who have progressed on previous treatment with a third-generation EGFR-TKI.
-
CTIS ↗ - 2024-519901-36-00CTIS ↗
LIBTAYO 350 mg concentrate for solution for infusion.
Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%
- 2025-522288-13-00CTIS ↗
Tarlatamab, Tarlatamab
Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2
-
CT.gov ↗ -
CT.gov ↗